Severe liver disease
Conditions
Interventions
Control group:Conventional regional citrate anticoagulation
Intervention group:Conventional regional citrate anticoagulation combine with low dose low molecular weight heparin anticoagulation
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.A history of chronic liver disease, total bilirubin >= 12 mg/dL (205 µmol/L), and no limit on the international normalized ratio (INR) of prothrombin time; 2.Intended to undergo artificial liver treatment with citrate anticoagulation, with the treatment mode being sequential plasma exchange combined with double plasma molecular adsorption system (DPMAS + PE), and the total treatment duration is 4 hours; 3.Age ranging from 18 to 75 years old, with no gender restrictions; 4.Patients at medium to high risk of extracorporeal circulation failure; 5.Consent to participate in this study.
Exclusion criteria
Exclusion criteria: 1.The patient has the following conditions: a history of malignant tumor or suspected malignant tumor, plans to receive non-liver organ transplantation or has undergone any organ transplantation. 2.Contraindications for citrate anticoagulation: shock, or uncorrected hypoxemia. 3.Contraindications for heparin-like drugs: extremely high risk of bleeding (active bleeding), history of allergy to heparin-like drugs, heparin-induced thrombocytopenia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Extracorporeal circulation failure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical routine monitoring items such as electrolyte and blood gas analysis;Anti-Xa;Clinical routine monitoring items such as blood routine, blood biochemistry, and coagulation.; | — |
Countries
China
Contacts
Public ContactYuanji Ma
West China Hospital of Sichuan University
Outcome results
None listed